Business Wire

REVEAL GENOMICS® HER2DX® Genomic Test to Be Validated in Pivotal ECOG-ACRIN CompassHER2 pCR Trial in HER2+ Breast Cancer

Share

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, today announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX® within the framework of the ongoing CompassHER2 pCR Trial. This study is led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), a scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer, comprising nearly 1400 member institutions in the United States and around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240509117263/en/

The CompassHER2 pCR Trial (also EA1181) is a single-arm phase II neoadjuvant study that successfully enrolled 2175 patients with stage II or IIIa HER2-positive (HER2+) breast cancer. Now in follow-up, this trial seeks to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with a pathologic complete response (pCR) after 3 months of pre-operative treatment with standard THP (single-agent taxane chemotherapy plus trastuzumab and pertuzumab [HP], both targeted drugs). If testing shows pCR at the time of surgery, patients will then complete a year of HP plus hormonal therapy and radiation, if indicated.

If the study's results validate this approach, it would allow patients to have fewer side effects and better quality of life. The neoadjuvant setting offers the opportunity to use pCR as a functional biomarker to identify patients with excellent outcomes and refine treatment to maximize benefit and minimize toxicity. The primary objective of the trial is 3-year recurrence-free survival, and pCR is a secondary endpoint.

In this collaboration, the CompassHER2 pCR Trial protocol has been amended to include the evaluation of the HER2DX® genomic test as a key secondary correlative endpoint. HER2DX® pCR-score and HER2DX® risk-score will be analyzed in baseline pre-treatment samples from most trial participants, linking these scores directly to patient outcomes.

The principal investigator of the CompassHER2 pCR Trial, Dr. Nadine M. Tung, commented, "Integrating HER2DX®'s predictive capabilities into our trial represents a significant opportunity in our quest to tailor treatments to the individual, not just the cancer type. If proven and validated, this assay could fundamentally change our approach to treating HER2-positive breast cancer."

Previous retrospective validation involving 765 patients with early-stage HER2+ breast cancer who received neoadjuvant therapy highlighted the HER2DX® pCR-score's ability to distinguish patients with a high pCR rate of 80-90% after treatment with single taxane, trastuzumab, and pertuzumab.

REVEAL GENOMICS' CEO, Patricia Villagrasa, added, "The inclusion of HER2DX® in the CompassHER2 pCR Trial is a testament to our commitment to advancing breast cancer treatment. By providing a more nuanced understanding of HER2-positive cancers, HER2DX® will play a crucial role in shaping the future of personalized therapy and improving patient outcomes."

HER2DX® in the CompassHER2 pCR Trial: Guiding the way to personalized medicine

The inclusion of HER2DX® in the CompassHER2 pCR Trial seeks to corroborate these initial findings, providing Level 1 evidence to support the selection of an optimized therapy regimen. Specifically, it seeks to validate the use of a single taxane-based regimen over traditional multi-agent chemotherapy, potentially revolutionizing the treatment approach for HER2-positive breast cancer by enabling more personalized, less intensive treatment strategies.

This pivotal collaboration represents a significant step towards personalized medicine in the management of early-stage HER2-positive breast cancer.

About HER2DX®️

HER2DX®️ is the world’s first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS®️ since January 2022, HER2DX® is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.

HER2DX®️ is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e. tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.

HER2DX®️ predicts:

  • Risk of relapse score (high vs. low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.
  • pCR likelihood score (high vs. medium vs. low): the likelihood of a patient responding to anti-HER2-based treatment before surgery.
  • ERBB2 score (high vs. medium vs. low): the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low and HER2+ breast cancer.

About ECOG-ACRIN

ECOG-ACRIN is renowned for advancing precision medicine and biomarker research through its leadership of major clinical trials that integrate cutting-edge genomic approaches. Through the CompassHER2 (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer) Trial Program, ECOG-ACRIN is collaborating with the Alliance for Clinical Trials in Oncology to investigate the optimization of therapy in patients with HER2+ breast cancer. The CompassHER2 pCR Trial (NCT04266249) was the first to open in this program, funded by the National Cancer Institute, part of the US National Institutes of Health.

Web: www.ecog-acrin.org, X: @eaonc. Other: Facebook, LinkedIn, and Instagram.

About REVEAL GENOMICS ®️

REVEAL GENOMICS, S.L. is a biotechnology start-up seeking to change the way biomarkers are used in oncology. It is focused on developing innovative diagnostic tools to define the best therapeutic options for patients with cancer. The company uses pioneering techniques, sophisticated computer applications, and machine learning to reveal new cancer research data.

REVEAL GENOMICS, S.L. is a spin-off company of Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona (U.B.), and Vall d’Hebron Institute of Oncology (VHIO).

REVEAL GENOMICS® and HER2DX® are registered trademarks of REVEAL GENOMICS, S.L.

Web: www.reveal-genomics.com. X: @revealgenomics

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Further information: Adriana Herrera, aherrera@reveal-genomics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

QPS Announces New Global Clinical Research Operations Leadership20.6.2024 20:00:00 EEST | Press release

QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medical affairs, regulatory affairs, data services, and clinical operations units with the existing successful QPS Phase I clinics. The enhanced global capabilities will help QPS satisfy the need for agility, flexibility, and speed in the quickly evolving global drug development community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620868635/en/ QPS Holdings, LLC corporate headquarters in Delaware Technology Park in Newark, Delaware. This location is also the QPS Bioanalysis Laboratory Center of Excellence for small and large molecule drug development. (Photo: Business Wire) “This addition of Mr. Derek Grimes to the QPS Global Leadership Team will enhance our ability to collaborate across business units to offer comprehensive

Mary Kay Inc. Presents New Findings on Skin Care Advances and the Use of Computational Tools in Identifying Skin Sensitivity20.6.2024 19:03:00 EEST | Press release

Mary Kay Inc., a global leader in skin care innovation, recently revealed the results of two breakthrough research studies: first, an antioxidant treatment that can diminish the visible effects of pollution and aging on human skin; and second, a focus on the applications of computational tools to accurately predict the safety and potential reactions of human skin to various cosmetic ingredients. These findings were shared by Mary Kay scientists at the 2024 Society of Investigative Dermatology (SID) meeting in Dallas, Texas. The company was a silver-level sponsor of the event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620935246/en/ Mary Kay Inc. recently revealed the results of two breakthrough research studies at the 2024 Society of Investigative Dermatology. (Photo: Mary Kay Inc.) “Mary Kay scientists are at the forefront of skin care research, and we’re pleased to share our latest findings with the broader scientif

Spot by NetApp Achieves FinOps Foundation's Certified Platform Certification20.6.2024 18:00:00 EEST | Press release

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Spot by NetApp has achieved the FinOps Certified Platform certification from the FinOps Foundation, validating the platform's ability to provide the depth and breadth of capabilities organizations need to practice sound cloud financial management. Also, Spot by NetApp has expanded its certified platform with the general availability of its Cost Intelligence and Billing Engine solutions. As organizations move increasing amounts of their workloads to the cloud, especially to fuel the development of AI applications, balancing the competing needs of infrastructure and financial efficiency becomes more difficult. Overprovisioning cloud resources results in wasted expenses, but under-provisioning can slow business operations and stifle innovation. The traditional approach of standalone FinOps tools, with their focus on cost cutting, fall short of meeting these evolved requirements to deliver cost-effect

The Dennemeyer Group selects Talkdesk to support its mission of being the first-choice partner for intellectual property globally20.6.2024 17:46:00 EEST | Press release

Talkdesk®, Inc., a global provider of artificial intelligence (AI)-powered customer experience (CX) technology that serves enterprises of all sizes, announced today that Dennemeyer, anintellectual property (IP) full-service provider managing over three million IP rights of over 8,000 customers globally, has chosen Talkdesk to streamline its CX. With more than 60 years of experience in the industry and over 20 offices worldwide, the Dennemeyer Group offers high-quality services for the protection and management of IP rights. As part of this, providing great CX is one of its priorities for the present and future. Dennemeyer ran a request for proposal to identify an expert who could implement a unified, integrated solution to reduce duplicated effort, save time, and deliver the best possible experience for its customers. The Dennemeyer Group will deploy multiple Talkdesk solutions to achieve these goals. Talkdesk CX Cloud™ will provide the organization with an AI-powered, modern, cloud-ba

Step Into the Future of Trading With AvaFutures, Powered by AvaTrade20.6.2024 16:55:00 EEST | Press release

Award-winning online trading broker, AvaTrade, has launched AvaFutures, a revolutionary futures trading platform designed to transform the retail futures trading space. AvaFutures simplifies the account opening and funding processes, allowing customers to sign up, fund their accounts using credit cards or other electronic methods, and start trading within minutes. The broker also offers a transparent pricing scheme with attractive commissions and no hidden fees, while customers can manage accounts online or access 24/5 support in over 10 languages, all free of charge. In addition, traders can now access CME Group’s deeply liquid, capital efficient futures contracts – available in Micro, E-mini, and Standard size – across Equity Index, Metals, Energy, FX, Cryptocurrencies, Agriculture, and Interest Rates markets, as well as other international markets/exchanges. The advanced MT5 platform offered by AvaFutures, provides traders with advanced charting capabilities, automated trading, in-d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye